Lilly, Gilead impress with Q3 sales growth


It's another big earnings day in Pharma-land, with Eli Lilly posting the results of a "great quarter," and Elan managed gains despite shrinking new-scrip numbers. Gilead Sciences boosted HIV drug sales and royalty revenues, growing sales by 31 percent. Here's the skinny:

Lilly posted $941.8 million in third-quarter net income, way up from last year's $465.6 million loss on charges. More impressively, however, the company managed to boost sales by 6.8 percent during a quarter when its rivals had a tough time on the revenue side.

Sales came in at $5.56 billion, on higher demand and higher prices; the antipsychotic Zyprexa, antidepressant Cymbalta, ED remedy Cialis, and cancer drug Alimta all posted gains. One caveat from Deutsche Bank analyst Barbara Ryan: To keep the sales growth coming, "[t]hey're probably going to have to continue to make acquisitions such as the one they did with ImClone." Fair?


Veeva 2019 Unified Clinical Operations Survey

Share your thoughts in this quick survey. The first 50 qualified respondents will receive a $5 Amazon gift card, and, in appreciation for your time, all qualified survey respondents will be entered in a drawing to win a $50 Amazon gift card.

Meanwhile, Elan followed the footsteps of several other drugmakers in reporting a third-quarter profit and raising its full-year earnings forecast--despite smaller-than-expected growth in sales. The company cut R&D and administrative costs by 12 percent, impressing analysts, who are expecting sales of the multiple sclerosis drug Tysabri to continue increasing. This quarter the drug grew 19 percent to some $207 million, despite falling new-scrip numbers.

Gilead posted a 42 percent boost in third-quarter profits to $673.3 million, benefiting from royalty revenues on the antiviral drug Tamiflu. The company's HIV drug sales also grew, with its combo pill Atripla posting 42 percent gains to $605 million. Total revenues rose 31 percent to $1.8 billion. The numbers met analyst expectations, but that wasn't enough for investors; the stock dropped some 2 percent yesterday.

- get more from Reuters
- read the Irish Independent piece
- check out the coverage from The Street